MSC-428 (Mercureid immunotherapy nanoparticles)

Indicaton

MSC-428 is an immuno-modulating multi-target mixed agonist/antagonist.
Extracellular targets: PD-1, CD19, CD25, CD38
Intracellular target: ZAP-70 kinase

Therapeutic indications

Type of product

Table

Phase

Marketed
Partnering status

Not partnered
Available in

Ukraine, CIS

You may also be interested in

AUP-16 (AUP1602-C)

AUP-16 is a multi-therapy live bacterial vector for chronic wounds: Diabetic Foot, Leg & Pressure Ulcers

Phase II started

Herzuma (trastuzumab)

Multiple indications in metastatic breast cancer, early breast cancer and metastatic gastric cancer

Marketed

Truxima (rituximab)

Multiple indications in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis, Granulomatosis with polyangiitis and microscopic polyangiitis and Pemphigus vulgaris

Marketed

MSC-428 (Mercureid immunotherapy nanoparticles)

Indicaton

Therapeutic indications

Type of product

Company

Table

You may also be interested in

AUP-16 (AUP1602-C)

Herzuma (trastuzumab)

Truxima (rituximab)